Anidulafungin

證據等級: L5

預測適應症: 0 個

Anidulafungin: Repurposing Evaluation (No TxGNN Predictions Currently Available)

One-Sentence Summary

Anidulafungin (DB00362) is an echinocandin antifungal agent with one active registration in Malaysia. The current Evidence Pack contains no TxGNN repurposing predictions for this drug — the predicted_indications list is empty — meaning a standard repurposing evaluation cannot be completed at this stage. Critical upstream data gaps in the original approved indication, mechanism of action, and safety profile must be resolved before the pipeline can produce actionable output.

Quick Overview

Item	Content
Original Indication	Not available in current data
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — no predictions to evaluate
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why No Prediction Was Generated

Currently, detailed mechanism of action data is not available. Based on its DrugBank classification (DB00362), Anidulafungin belongs to the echinocandin class of antifungal agents. Echinocandins act by inhibiting 1,3-β-D-glucan synthase, an enzyme essential for fungal cell wall integrity that has no mammalian equivalent — giving this drug class a highly selective safety profile.

The absence of TxGNN predictions most likely stems from one or more of the following upstream failures:

No approved indications were loaded — original_indications is an empty list, which may have prevented the drug from being correctly anchored in the knowledge graph.
MOA data is missing — without mechanistic annotation, the graph-based traversal used by TxGNN may have scored no candidate disease nodes above the reporting threshold.
Licence detail fields are blank — even though 1 NPRA registration exists, all structured fields (product name, dosage form, approved indication text) returned empty strings, suggesting a parsing or data-retrieval failure at the NPRA query step.

Until these inputs are corrected and the prediction pipeline re-run, no repurposing candidates can be evaluated.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
Not returned	Not returned	Not returned	Not returned

Although the NPRA query on 2026-03-27 returned a result_count of 1, all structured fields within the licence record are blank. The raw response from NPRA should be inspected to determine whether the issue is a field-mapping mismatch in config/fields.yaml or an upstream data quality problem in the NPRA database itself.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug interactions) are currently flagged as data gaps or returned empty. The DDI query returned zero interactions with a status of not_found. No safety summary can be produced until the package insert is retrieved and parsed.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline produced zero repurposing candidates for Anidulafungin, and every critical data input — approved indication, mechanism of action, safety warnings, and NPRA licence details — is currently unavailable. There is no evidence base on which to make a repurposing recommendation.

To proceed, the following is needed:

[Blocking — DG001] Download and parse the NPRA/TFDA package insert PDF to extract approved indications, key warnings, and contraindications; without this, safety pre-screening (S1 gate) cannot be entered
[High — DG002] Query the DrugBank API for Anidulafungin’s mechanism of action (DB00362) to enable mechanistic relevance analysis
[High] Investigate why the single NPRA licence record returned all blank fields — check the field mapping in config/fields.yaml against the actual NPRA response structure and correct the parser in scripts/process_fda_data.py
[High] Re-run scripts/run_kg_prediction.py after populating the original indication and MOA fields; verify that Anidulafungin (DB00362) is present and correctly mapped in data/external/drugbank_vocab.csv
[Medium] Once predictions are available, collect clinical trial and PubMed literature evidence for the top-ranked predicted indication and re-issue this report at Evidence Level L2 or above before any go/no-go decision
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.